BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Serine/arginine-rich splicing factor 2 (SRSF2); splicing factor 3B subunit 1 (SF3B1)

May 5, 2016 7:00 AM UTC

Mouse studies suggest inhibiting SF3B1 could help treat SRSF2-mutant AML. In a mouse model of SRSF2-mutant AML, an SF3B1 inhibitor tool compound that blocks missplicing of mutant SRSF2 increased survi...